MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
Company profile
Ticker
INKT
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AgenTus Therapeutics, Inc., AgenTus Therapeutics, Inc.
SEC CIK
Corporate docs
Subsidiaries
AgenTus Therapeutics Limited • AgenTus Therapeutics SA ...
INKT stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
21 Mar 24
8-K
MiNK Reports Fourth Quarter and Year-End 2023 Results
21 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
29 Feb 24
8-K
Entry into a Material Definitive Agreement
14 Feb 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
MiNK Therapeutics Reports Third Quarter 2023 Results
9 Nov 23
8-K
Departure of Directors or Certain Officers
17 Oct 23
S-8
Registration of securities for employees
11 Aug 23
8-K
MiNK Therapeutics Reports Second Quarter 2023 Results
10 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
Transcripts
INKT
Earnings call transcript
2023 Q4
21 Mar 24
INKT
Earnings call transcript
2023 Q3
9 Nov 23
INKT
Earnings call transcript
2023 Q1
11 May 23
INKT
Earnings call transcript
2022 Q4
21 Mar 23
INKT
Earnings call transcript
2022 Q3
6 Nov 22
INKT
Earnings call transcript
2022 Q3
3 Nov 22
INKT
Earnings call transcript
2022 Q2
13 Aug 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.40 mm | 6.40 mm | 6.40 mm | 6.40 mm | 6.40 mm | 6.40 mm |
Cash burn (monthly) | 1.41 mm | 1.48 mm | 1.74 mm | 2.11 mm | 1.40 mm | 1.43 mm |
Cash used (since last report) | 9.69 mm | 10.19 mm | 11.98 mm | 14.52 mm | 9.66 mm | 9.84 mm |
Cash remaining | -3.29 mm | -3.79 mm | -5.59 mm | -8.12 mm | -3.26 mm | -3.44 mm |
Runway (months of cash) | -2.3 | -2.6 | -3.2 | -3.8 | -2.3 | -2.4 |
Institutional ownership, Q3 2023
64.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 37 |
Opened positions | 1 |
Closed positions | 10 |
Increased positions | 7 |
Reduced positions | 17 |
13F shares | Current |
---|---|
Total value | 771.39 mm |
Total shares | 22.25 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
AGEN Agenus | 21.52 mm | $38.31 mm |
Vanguard | 234.18 k | $257.60 mm |
Geode Capital Management | 90.16 k | $105.52 mm |
BLK Blackrock | 80.50 k | $88.55 mm |
Captrust Financial Advisors | 61.80 k | $67.98 mm |
Renaissance Technologies | 57.70 k | $63.00 k |
Oracle Investment Management | 36.90 k | $40.59 mm |
STT State Street | 25.70 k | $30.07 mm |
BAC Bank Of America | 25.40 k | $27.94 mm |
Ubs Oconnor | 21.59 k | $25.26 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Mar 24 | Peter Behner | Common Stock | Grant | Acquire A | No | No | 0.95 | 16,185 | 15.38 k | 75,027 |
1 Mar 24 | Barbara Ryan | Common Stock | Grant | Acquire A | No | No | 0.95 | 18,685 | 17.75 k | 86,617 |
1 Mar 24 | Wiinberg Ulf | Common Stock | Grant | Acquire A | No | No | 0.95 | 15,790 | 15.00 k | 90,333 |
1 Mar 24 | Corvese Brian | Common Stock | Grant | Acquire A | No | No | 0.95 | 18,816 | 17.88 k | 365,527 |
16 Jan 24 | Buell Jennifer | Stock Option Common Stock | Grant | Acquire A | No | No | 0.87 | 660,919 | 575.00 k | 660,919 |
16 Jan 24 | Buell Jennifer | Stock Option Common Stock | Grant | Acquire A | No | No | 0.87 | 500,000 | 435.00 k | 500,000 |
News
12 Health Care Stocks Moving In Monday's Intraday Session
8 Apr 24
MiNK Therapeutics Announces Preclinical Activity Of MiNK-215 Against Colorectal Cancer Liver Metastases At AACR
8 Apr 24
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
5 Apr 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
5 Apr 24
HC Wainwright & Co. Maintains Buy on MiNK Therapeutics, Lowers Price Target to $9
21 Mar 24